Site icon Impactiviti

Impactiviti Daily 021910


Big news on the leukemia front: NovartisTasigna gets priority FDA review for newly-diagnosed patients; and Roche/Genentech‘s Rituxan approved for CLL.

A quarter of new prescriptions go unfilled.

Statins: cardiovascular benefits far outweigh the diabetes risks – Statin drugs raise the risk of diabetes significantly, but the danger appeared puny compared with their cardiovascular benefits, researchers found in a meta-analysismore

Gilead looking to ride a Quad to victory in HIV – Gilead Sciences has gone some way to ensuring that its dominance of the HIV market continues after phase II data from its “Quad” pill presented at the Conference on Retroviruses and Opportunistic Infections showed non-inferiority to its second best-selling drug, Atriplamore

Pharma eMarketing round-up: some great links and a big, thought-provoking question.


Product launch training – If you’ve got new product launches in the plans, we have top vendor/providers to help with therapeutic area training, product modules, animations, meetings and events – just let us know. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Even Me-Too Drugs get the blues


I don’t recommend you try this at home! But what happens when an iMac meets a house fire? The result is…surprising, to say the least!


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Exit mobile version